Insider Buying: Dr. Martens (LON:DOCS) Insider Acquires £150.36 in Stock

Dr. Martens plc (LON:DOCS) insider Giles Wilson bought 179 shares of the stock in a transaction on Tuesday, August 11th. The shares were bought at an average cost of GBX 84 per share, for a total transaction of £150.36.

Giles Wilson also recently made the following trade(s):

• On Thursday, June 25th, Giles Wilson acquired 68,313 shares of Dr. Martens stock. The shares were bought at an average price of GBX 72 per share, for a total transaction of £49,185.36.
• On Thursday, June 11th, Giles Wilson bought 202 shares of Dr. Martens stock. The shares were purchased at an average cost of GBX 74 per share, for a total transaction of £149.48.

Dr. Martens Price Performance

Shares of LON:DOCS opened at GBX 88.07 on Friday. The stock has a market cap of £842.94 million, a price-to-earnings ratio of 36.70, a PEG ratio of 6.40 and a beta of 0.26. The company has a debt-to-equity ratio of 108.85, a current ratio of 2.61 and a quick ratio of 1.13. Dr. Martens plc has a 12 month low of GBX 59.15 and a 12 month high of GBX 100.87. The stock’s 50 day moving average price is GBX 75.19 and its 200 day moving average price is GBX 69.41.

Dr. Martens (LON:DOCS) last issued its quarterly earnings results on Tuesday, May 19th. The company reported GBX 4.20 earnings per share (EPS) for the quarter. Dr. Martens had a return on equity of 6.89% and a net margin of 3.11%.The firm had revenue of £764.90 million during the quarter. Equities research analysts anticipate that Dr. Martens plc will post 2.5809394 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently weighed in on DOCS. Berenberg Bank dropped their price target on Dr. Martens from GBX 114 to GBX 110 and set a “buy” rating on the stock in a research report on Tuesday, May 19th. Royal Bank Of Canada restated a “sector perform” rating and set a GBX 100 price objective on shares of Dr. Martens in a research report on Tuesday, June 2nd. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, Dr. Martens has an average rating of “Moderate Buy” and a consensus price target of GBX 105.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.